GlassScriptPhysician profile
Payam Sadry
NPI 1558717611
$9,120.10
in general payments reported to CMS, 2019-2025
43 companies · $2,634 in 2025
The $2,634 reported for 2025 was more than what 77% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $151 · 2021: $251 · 2022: $692 · 2023: $2,455 · 2024: $2,937 · 2025: $2,634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,992 · Education: $33.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,992.35 |
| Education | $33.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,259.17 | 2022-2025 | Botox, Ubrelvy, Qulipta |
| Ucb, INC. | $1,097.09 | 2022-2025 | Briviact, Nayzilam, Fintepla |
| Novartis Pharmaceuticals Corporation | $868.17 | 2022-2025 | |
| Biogen, INC. | $784.08 | 2021-2025 | Vumerity, Tysabri, Avonex |
| Pfizer INC. | $561.45 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $529.40 | 2023-2025 | Ingrezza, Ongentys |
| Argenx US, INC. | $471.95 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Neurelis, INC. | $300.39 | 2022-2025 | Valtoco |
| Eisai INC. | $292.12 | 2021-2025 | |
| Sk Life Science, INC. | $232.41 | 2022-2025 | |
| Emd Serono, INC. | $230.69 | 2022-2025 | Mavenclad |
| Genentech USA, INC. | $211.88 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Lilly USA, LLC | $196.10 | 2023-2024 | Reyvow, Emgality, Amyvid |
| Catalyst Pharmaceuticals, INC. | $158.65 | 2023-2025 | Fycompa |
| Livanova USA, INC. | $158.37 | 2023-2025 | Vns Therapy Sentiva Model 1000 Generator |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Payam Sadry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.